Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Perhaps to the surprise of some, a few non-technology companies have seen wildly strong performances YTD, with their lower-beta nature providing a nice shield against volatility.